Review of NICE Technology Appraisal Guidance No 121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma

The Institute was proposing that the consideration to review the existing guidance should be deferred until 2015.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal. We will therefore defer the review of the original guidance until 2015 when the results of ongoing trials are available. At this point the evidence base will again be assessed to ascertain the need for a review of the current guidance.

October 2010

Appendix A: Review decision paper considered by the Institute’s Guidance Executive